In a 2017 published clinical study [113], [18F]26 was used for assessment of the PDE10A availability in the striatum of patients with progressive supranuclear palsy (PSP) and PD to possibly differentiate between these two neurodegenerative disorders by PET. This evidence concerns the gene PDE10A and Parkinson disease.